How big is National Research Corp.?

As of Jun 18, National Research Corp. has a market capitalization of 472.86 million and reported net sales of 141.30 million and net profit of 24.21 million over the latest four quarters.

As of Jun 18, National Research Corp. has a market capitalization of 472.86 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 141.30 million, while the sum of Net Profit for the same period is 24.21 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 31.28 million and Total Assets at 139.16 million.

What does National Research Corp. do?

National Research Corporation (NRC Health) provides analytics and insights for healthcare providers and payers, with a market cap of $472.86 million. As of March 2025, it reported net sales of $34 million and a net profit of $6 million.

Overview:<BR>National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers and payers in the Miscellaneous industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 34 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 472.86 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 17.00<BR>- Dividend Yield: 2.47%<BR>- Debt Equity: 2.11<BR>- Return on Equity: 82.18%<BR>- Price to Book: 15.94<BR><BR>Contact Details:<BR>- Address: 1245 Q St, LINCOLN NE: 68508-1430<BR>- Tel: 1 402 4752525<BR>- Fax: 1 402 4759061<BR>- Website: https://nrchealth.com/

Should I buy, sell or hold National Research Corp.?

Who are in the management team of National Research Corp.?

As of March 2022, the management team of National Research Corp. includes Mr. Michael Hays as President and CEO, with Mr. John Nunnelly as Lead Independent Director, and Dr. Donald Berwick and Ms. JoAnn Martin as Independent Directors.

As of March 2022, the management team of National Research Corp. includes Mr. Michael Hays, who serves as the President, Chief Executive Officer, and Director. Additionally, Mr. John Nunnelly is the Lead Independent Director. The board also includes Dr. Donald Berwick and Ms. JoAnn Martin, both serving as Independent Directors.

Is National Research Corp. technically bullish or bearish?

As of September 8, 2025, National Research Corp. shows a neutral trend with mixed signals, as weekly indicators are mildly bullish while daily indicators are mildly bearish, and the stock has underperformed the S&P 500 with a year-to-date return of -9.92%.

As of 8 September 2025, the technical trend for National Research Corp. has changed from mildly bearish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. However, the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mildly bullish signal on the weekly chart but a mildly bearish signal on the monthly chart. The KST is mildly bearish weekly but mildly bullish monthly, and the Dow Theory presents a mildly bullish signal weekly but mildly bearish monthly. <BR><BR>In terms of performance, the stock has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -9.92% versus the S&P 500's 12.22%, and a one-year return of -27.18% compared to 17.14% for the index.

Is National Research Corp. overvalued or undervalued?

As of October 17, 2025, National Research Corp. is considered overvalued with a valuation grade of "expensive," reflected by its high financial ratios and a year-to-date return of -34.18%, significantly underperforming the S&P 500's 13.30%.

As of 17 October 2025, the valuation grade for National Research Corp. moved from very expensive to expensive, indicating a slight improvement in perceived value. The company is currently considered overvalued based on its financial metrics. Key ratios include a P/E ratio of 17, an EV to EBITDA of 11.75, and a Price to Book Value of 14.27, which are all higher than its peer, Psychemedics Corp., which has a P/E of -8.09 and an EV to EBITDA of 14.32.<BR><BR>In comparison to the broader market, National Research Corp. has significantly underperformed, with a year-to-date return of -34.18% compared to the S&P 500's 13.30%. This stark contrast in performance further supports the conclusion that the stock is overvalued relative to its current financial standing and market conditions.